CLINICAL_TRIALS ClinicalTrials.gov record update

An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00101959
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:28.045622+00:00
Published At: 2013-08-06T00:00:00+00:00
Record Updated At: 2013-08-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsing-Remitting Multiple Sclerosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-08-06"
protocolSection.identificationModule.nctId: "NCT00101959"
protocolSection.identificationModule.officialTitle: "An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-\u00df-1a 30 Mcg qw IM (Avonex\u00ae) or Glatiramer Acetate 20 mg qd SC (Copaxone\u00ae) to Those Randomized to IFN-\u00df-1a 44 Mcg Tiw SC (Rebif\u00ae), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.